Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid.

@article{Law2009CostsAC,
  title={Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid.},
  author={Michael R Law and Stephen B. Soumerai and Alyce S Adams and Sumit Ranjan Majumdar},
  journal={Archives of internal medicine},
  year={2009},
  volume={169 21},
  pages={
          1969-74
        }
}
BACKGROUND Direct-to-consumer advertising (DTCA) is assumed to be a major driver of rising pharmaceutical costs. Yet, research on how it affects costs is limited. Therefore, we studied clopidogrel, a commonly used and heavily marketed antiplatelet agent, which was first sold in 1998 and first direct-to-consumer advertised in 2001. METHODS We examined pharmacy data from 27 Medicaid programs from 1999 through 2005. We used interrupted time series analysis to analyze changes in the number of… CONTINUE READING
BETA

From This Paper

Figures and tables from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 38 REFERENCES

Ad$ummary

  • TNS Media Intelligence
  • New York, NY: TNS Media Intelligence;
  • 2005
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…